Editas Medicine
EDIT
About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Employees: 226
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
207% more call options, than puts
Call options by funds: $1.83M | Put options by funds: $596K
78% more capital invested
Capital invested by funds: $51M [Q1] → $90.9M (+$39.9M) [Q2]
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
8% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 52
1% less funds holding
Funds holding: 193 [Q1] → 191 (-2) [Q2]
3.67% less ownership
Funds ownership: 53.04% [Q1] → 49.37% (-3.67%) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Mitchell S. Kapoor
|
$5
|
Buy
Reiterated
|
5 Sep 2025 |
|
Wells Fargo
Yanan Zhu
|
$4
|
Equal-Weight
Maintained
|
3 Sep 2025 |
|
Baird
Joel Beatty
|
$6
|
Outperform
Maintained
|
13 Aug 2025 |
Financial journalist opinion
Based on 6 articles about EDIT published over the past 30 days
